Trump signs executive order to accelerate psychedelic drug research
Here's what it means for you.
This executive order could reshape the landscape of mental health treatment in the U.S.
What happened
Trump signed an executive order to accelerate research and approval of psychedelics for medical use.
The Context
- The order aims to address mental health issues such as depression, PTSD, and addiction.
- Advocates are hopeful that this will lead to a shift in federal drug policy regarding psychedelics.
- Concerns remain about the slow pace of federal drug policy changes despite this executive action.
Takeaway
The executive order could pave the way for broader acceptance and use of psychedelics in medical treatments.
Insights by A47 Intelligence
Capitol Hill news, legislation, and policy insight.
"The Hill specializes in U.S. politics and policy, with a focus on Capitol Hill developments and a reputation for insider reporting."
— A47 Editor
Trump’s Rogan-inspired psychedelics order stokes cautious optimism
President Donald Trump signed an executive order on April 18, 2026, aimed at loosening research restrictions on psychedelic medicine, inspired by a text from podcaster Joe Rogan. This order is designed to expedite the review process for psychedelic d...
News from the United States including domestic politics, society, and culture.
"Sky News is often seen as a center-right outlet in the UK, known for its rolling news coverage and emphasis on breaking stories and political affairs."
— A47 Editor
What is ibogaine? The psychedelic drug that Trump may make available
President Donald Trump has signed an executive order aimed at expediting the review process for psychedelic drugs, including ibogaine, which is noted for its potential to treat post-traumatic stress disorder (PTSD) among military veterans. This order...
Medical reporting with scientific depth and public service tone.
"NPR is a nonprofit media organization offering thoughtful, in-depth journalism and storytelling, often with a liberal or progressive slant."
— A47 Editor
Trump's order is a milestone for proponents of using psychedelics as medicine
President Donald Trump has signed an executive order aimed at accelerating the research and approval of psychedelic substances, including psilocybin and ibogaine, for treating mental health conditions such as depression, PTSD, and addiction. This ini...
Global business headlines with AI angles.
"General business outlet that frequently covers AI."
— A47 Editor
New Psychedelics Push by Donald Trump Raises Questions About Federal Drug Policy Delays
Donald Trump has initiated a new order aimed at accelerating research into psychedelics, which has sparked discussions regarding the slow pace of federal drug policy reforms. This move seeks to address the growing interest in psychedelic substances f...